Get in touch
Please contact us to discuss how working with Myriad Associates can maximise and secure R&D funding opportunities for your business.
I would highly recommend Marc and the Myriad Associates team, They are thorough professionals and a pleasure to deal with. I can’t emphasize enough the value Marc brings to any project. His exemplary track record of success speaks for itself.Prof. Michael O'Dwyer
CSO, ONK Therapeutics
ONK Therapeutics was founded in 2015 with the goal of developing novel anti-cancer therapies using Natural Killer (NK) cells. NK cells are one of the body’s strongest defences against cancer, being one of the most tumour cytotoxic components of the human immune system. The company’s strategy is to develop novel, off the shelf, NK cell-based therapies for cancer. Further, the company is seeking to enhance these NK cells through the introduction of a series of genetic modifications, creating a technology platform that can be tailored to multiple cancers.
|Eligible R&D Project Value:||€4.3m grant received|
|Number of Employees:||n/a|
Marc Greatrex, Director of Grants at Myriad Associates was introduced to Prof Michael O’Dwyer, CSO at ONK Therapeutics at the National University of Ireland in Galway in August 2018. Michael was interested to learn whether their CAR-NK project would be suitable for public funding to which Marc quickly highlighted the Disruptive Technologies Innovation Fund as a great fit for the project and for ONK Therapeutics.
The Disruptive Technologies Innovation Fund is a €500 million fund established under Project Ireland 2040 and is run by the Department of Business, Enterprise and Innovation with administrative support from Enterprise Ireland. Marc and Michael started with creating an executive summary for the Expression of Interest and Michael recruited a best in class consortium of NUI Galway, Centre for Cell Manufacturing and Janssen Sciences Ireland UC, Part of Johnson and Johnson.
Myriad Associates helped ONK Therapeutics put together their expression of interest towards this fund which was a 20-page document covering project context, solution, impacts upon National Strategic Outcomes (NSOs) in Project Ireland 2040, project deliverables and business plan.
We were delighted when the project and ONK Therapeutics were shortlisted by the DTIF and asked to prepare a full stage 2 application.Marc Greatrex, Myriad Associates
Again, Myriad Associates helped ONK Therapeutics put together a full stage application starting with an executive summary along with the same world-class consortium from the Expression of Interest.
The full stage application comprised of a major consortium application of 25 pages with separate budgets and technical appendix from each consortium partner.
Following the submission of the documents and subsequent face to face interview with Department of Business, Enterprise & Innovation and administrative support from Enterprise Ireland – ONK Therapeutics with their consortium partners were successful and were one of 27 other projects shortlisted by the DTIF.
The total funding approved for the project is €4.3m, over 3 years to 2021 with the project starting in April 2019.
Marc and the Myriad team are such pros, his work ethic and attention to detail coupled with his strategy guidance is so compelling, his results speak for themselves, it can't be all down to luck.”Tony Killarney, Co-Founder, ONK Therapeutics